RankAlpha logo
Back to Rankings

AUPH

AuriniaC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The post-earnings bull case is that Aurinia is still showing clean LUPKYNIS growth, strong profitability, positive operating cash flow, and enough balance-sheet capacity to pursue buybacks and pipeline expansion at the same time. The Kezar transaction also creates a second leg of optionality beyond the legacy single-product story.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
2026 guidance was reiterated, not raised, which can disappoint after a strong run and makes the quarter look more like steady execution than acceleration.
Momentum
27
Value
66
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $19.00 · Bear $13.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum27 · Δ7d +18.5
Value66 · Δ7d +0.1
Sentiment55 · Δ7d +1.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
27
26% active weight
Current posture
7d trendSoftening
Δ7d
+18.5
Δ21d
-24.9
Value
66
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
55
34% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
+6.6
Why this grade

Composite grade C. Momentum 26.6 / Value 66.2 / Sentiment 54.9

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.97B
Beta
1.52
Shares Out
128.6M
P/E (TTM)
27.3
P/S (TTM)
7.59
P/FCF (TTM)
16.83
Rev YoY
+24.4%
EPS YoY
+53.1%
Gross Margin
+89.7%
Op Margin
+26.3%
Net Debt
-$323.19M
Current Ratio
5.55
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology